Connect with us

Life Sciences

HumanSignal Attains HIPAA Compliance for Label Studio Enterprise

Certification Underscores HumanSignal’s Commitment to Data Security and Privacy for Healthcare Data Labeling  HumanSignal is proud to announce the successful…

Published

on

This article was originally published by AITHORITY
HumanSignal Attains HIPAA Compliance for Label Studio Enterprise

Certification Underscores HumanSignal’s Commitment to Data Security and Privacy for Healthcare Data Labeling

 HumanSignal is proud to announce the successful attainment of HIPAA (Health Insurance Portability and Accountability Act) compliance for its flagship data labeling platform, Label Studio Enterprise. HIPAA compliance is a significant milestone for HumanSignal, demonstrating the company’s dedication to safeguarding sensitive healthcare data, and enabling healthcare organizations to take advantage of its cloud-based platform without the need to manage on-prem infrastructure.

Recommended: Predictions Series 2022: AiThority Interview with Anoop Ramachandran, Chief Technology Officer at Preciso

Healthcare organizations are applying machine learning and AI in many innovative ways, from accelerating research to improving patient care, which makes high quality, secure data labeling a critical part of the pipeline. This certification validates that Label Studio Enterprise adheres to the strict regulatory requirements set forth by HIPAA, ensuring the confidentiality, integrity, and availability of protected health information (PHI). Key benefits of Label Studio Enterprise achieving HIPAA compliance include:

  • Enhanced Data Security: The attainment of HIPAA compliance guarantees that Label Studio Enterprise employs robust security measures to protect PHI, safeguarding against unauthorized access or breaches.
  • Increased Trust and Confidence: Healthcare organizations can now confidently integrate Label Studio Enterprise into their machine learning pipeline and workflows, knowing that the platform meets the highest industry standards for data privacy and security.
  • Alignment with Industry Regulations: Achieving HIPAA compliance demonstrates HumanSignal’s commitment to compliance with the most stringent healthcare data protection regulations, ensuring customers meet their own regulatory requirements.
  • Cloud-based Hosting for Healthcare: This certification opens doors for healthcare providers, insurers, and other entities that demand the highest level of data security and compliance to use Label Studio Enterprise cloud.

Recommended: Predictions Series 2022: AiThority Interview with Dr. Arnaud Rosier, CEO & Founder at Implicity

“We are thrilled to announce our achievement of HIPAA compliance for Label Studio Enterprise,” said Michael Malyuk, CEO at HumanSignal. “This certification reflects our unwavering commitment to ensuring the highest standards of data security and privacy for healthcare applications. With the healthcare sector increasingly adopting machine learning and AI, we are proud to offer data labeling platform that enables efficiency, accuracy and data privacy.”

Recommended: Predictions Series 2022: AiThority Interview with David Low, CMO at Talkwalker

[To share your insights with us, please write to sghosh@martechseries.com]

The post HumanSignal Attains HIPAA Compliance for Label Studio Enterprise appeared first on AiThority.




machine learning

Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending